EU proposals to greatly increase access to health data and the use of real-world evidence in EU policy making could allow the prices of drugs for cancer, diabetes and other diseases to be renegotiated “based on the observed real-world effects,” according to the European Commission.
EU Health Data Project: More Use Of Real-World Evidence In Price Negotiations
The proposed European Health Data Space is expected to boost innovation in preventing, diagnosing and treating disease and to support the long-term competitiveness of the EU’s medical sector. The pharmaceutical industry has broadly welcomed the move but wants to see certain safeguards and guarantees put in place.
More from Europe
More from Geography
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.